Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LuDO-N trial of 177Lu-DOTATATE in children with refractory or relapsed high-risk neuroblastoma
2023-503684-42-00Phase 2Authorised
- Sponsor
- Karolinska University Hospital
- Start
- Jan 2021
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
- Countries
- 6
01
Overview
Phase 2, open-label, single-arm trial of lutetium Lu 177 dotatate in neuroblastoma, sponsored by Karolinska University Hospital. Primary endpoint: Response by Revised International Neuroblastoma Response Criteria. Planned start Jan 2021; status: authorised.
02
Drugs
lutetium Lu 177 dotatate
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on 2023-503684-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503684-42-00.